U-Protein Express Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $8.04M

U-Protein Express General Information

Description

Operator of a contract research organization intended to focus on recombinant protein production. The company offers fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications as well as produces and purifies recombinant proteins and antibodies via its r-PEx transient expression platform, thereby providing customers with custom antibody engineering and production services to support their research and development efforts.

Contact Information

Website
www.u-proteinexpress.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
ImmunoPrecise Antibodies
Primary Office
  • Utrecht Science Park
  • Yalelaan 62
  • 3584 CM Utrecht
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

U-Protein Express Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Aug-2017 $8.04M 00.000 Completed Generating Revenue
3. Grant 31-Mar-2015 Completed Generating Revenue
2. Early Stage VC Completed Startup
1. Spin-Off 01-Jan-2007 Completed Startup
To view U-Protein Express’s complete valuation and funding history, request access »

U-Protein Express Patents

  • 9

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

U-Protein Express Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2927428-A1 Novel polypeptide and uses thereof Inactive 17-Oct-2013 0000000000
EP-3057607-A1 Novel polypeptide and uses thereof. Inactive 17-Oct-2013 0000000000
US-20160333074-A1 Novel polypeptide and uses thereof Inactive 17-Oct-2013 0000000000
DE-602008000796-D1 Method for determining the amino acid sequence of peptides Active 15-Jan-2008 00000000000
EP-2081025-A9 Method for determining the amino acid sequence of peptides Active 15-Jan-2008 G01N33/6818
To view U-Protein Express’s complete patent history, request access »

U-Protein Express Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

U-Protein Express Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IPC-BioFarmind Other 000 0000 000000 0
Nederlandse Organisatie voor Wetenschappelijk Onderzoek Government 000 0000 000000 0
Utrecht Holdings Not-For-Profit Venture Capital Minority 000 0000 000000 0
To view U-Protein Express’s complete investors history, request access »

Ready to get started?

Request a free trial